文献速递糖尿病

2型糖尿病成人临终前降糖药物处方趋势:一项队列研究

Prescribing Trends of Glucose-Lowering Medications Near End of Life Among Adults With Type 2 Diabetes: A Cohort Study.
PubMed 文献 · Diabetes Care · 2025-01-01

该观察性队列研究纳入975407例年龄≥67岁的2型糖尿病医保受益人(2015-2019年),评估临终前1年降糖药物处方趋势并按衰弱分层。结果显示降糖药物使用从死亡前9-12个月的66.1%降至临终前4个月的60.8%(SMD 0.11;P<0.01),主要因非胰岛素药物使用减少;胰岛素使用在临终前增加,衰弱者更可能接受胰岛素。

要点

  • 临终前1年降糖药物使用从66.1%降至60.8%(SMD 0.11;P<0.01),主要由非胰岛素药物减少驱动。
  • 二甲双胍使用从40.7%升至46.5%(SMD -0.12),磺脲类从37.0%降至31.8%(SMD 0.11)。
  • 短效和长效胰岛素使用在临终前均增加,衰弱者更可能接受胰岛素。

核心结论

  • 临终前1年降糖药物使用下降,主要因非胰岛素药物使用减少;胰岛素使用在临终前增加,尤其在衰弱个体中,凸显临终管理需谨慎。

研究设计与样本

  • 观察性队列研究,纳入975407例年龄≥67岁、居住于社区的2型糖尿病医保受益人,研究年份为2015-2019年。

主要发现

  • 临终前1年内降糖药物使用从2015年第一个6个月期间的71.4%轻度升至2019年第二个6个月期间的72.9%(SMD -0.03)。
  • 二甲双胍使用从40.7%升至46.5%(SMD -0.12),为增幅最明显者;磺脲类从37.0%降至31.8%(SMD 0.11),为降幅最大者。
  • 总体降糖药物使用从死亡前9-12个月的66.1%降至临终前4个月的60.8%(SMD 0.11;P<0.01),由非胰岛素药物使用减少驱动。
  • 短效和长效胰岛素使用在临终前均增加,衰弱者更可能接受胰岛素。
  • 钠-葡萄糖共转运蛋白2抑制剂和胰高血糖素样肽1受体激动剂虽不常见,但近年使用频率增加。

临床怎么用

  • 原文结论指出临终前胰岛素使用增加尤其在衰弱个体中,凸显临终管理需谨慎,未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess prescribing trends of glucose-lowering medications in the last year of life among older adults with type 2 diabetes (T2D) and explore whether frailty is associated with differential prescribing. RESEARCH DESIGN AND METHODS: In this observational cohort study of Medicare beneficiaries aged ≥67 years (2015-2019) with T2D, we assessed temporal trends in prescribing a glucose-lowering medication, stratified by frailty. The main outcome included glucose-lowering medication fills within 1 year of death. RESULTS: Among 975,407 community-dwelling Medicare beneficiaries with T2D, the use of glucose-lowering medications within 1 year of death slightly increased from 71.4% during the first 6-month period in 2015 to 72.9% (standardized mean difference [SMD] -0.03) during the second 6-month period in 2019. The most pronounced increase in use was observed for metformin (40.7% to 46.5%, SMD -0.12), whereas the largest decrease was observed for sulfonylureas (37.0% to 31.8%, SMD 0.11). Overall glucose-lowering medication use decreased from 66.1% in the 9 to 12 months before death to 60.8% in the last 4 months of life (SMD 0.11; P < 0.01), driven by reduced noninsulin medication use. The use of short-acting and long-acting insulin both increased near death, with frailer individuals more likely to receive insulin. Sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists, although less common, became more frequent in more recent years. CONCLUSIONS: The use of glucose-lowering medications declined in the last year of life, mainly due to reduced noninsulin use. Insulin use increased near death, particularly among frailer individuals, highlighting the need for careful end-of-life management.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Kutz A, Kim DH, Liu J, et al. Prescribing Trends of Glucose-Lowering Medications Near End of Life Among Adults With Type 2 Diabetes: A Cohort Study. Diabetes Care. 2025. PMID: 39746144. doi:10.2337/dc24-1795

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。